Covea Finance Has $2.16 Million Position in The Cooper Companies, Inc. (NASDAQ:COO)

Covea Finance lessened its position in The Cooper Companies, Inc. (NASDAQ:COO) by 26.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,500 shares of the medical device company’s stock after selling 8,500 shares during the quarter. Covea Finance’s holdings in Cooper Companies were worth $2,160,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of COO. Ashton Thomas Securities LLC bought a new stake in Cooper Companies during the third quarter worth about $25,000. Covestor Ltd increased its position in shares of Cooper Companies by 144.9% during the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after purchasing an additional 200 shares during the last quarter. Brown Brothers Harriman & Co. raised its stake in shares of Cooper Companies by 191.0% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after purchasing an additional 275 shares in the last quarter. Friedenthal Financial acquired a new stake in shares of Cooper Companies in the 3rd quarter valued at approximately $50,000. Finally, Cromwell Holdings LLC bought a new position in shares of Cooper Companies in the third quarter valued at $52,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Performance

COO opened at $89.11 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The business has a fifty day simple moving average of $97.56 and a 200 day simple moving average of $98.94. The Cooper Companies, Inc. has a 1 year low of $84.76 and a 1 year high of $112.38. The company has a market capitalization of $17.78 billion, a PE ratio of 45.70, a price-to-earnings-growth ratio of 2.40 and a beta of 0.99.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the business posted $0.87 earnings per share. Cooper Companies’s quarterly revenue was up 9.8% on a year-over-year basis. Research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Morgan Stanley dropped their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Citigroup reduced their price target on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a report on Friday, December 6th. Wells Fargo & Company upped their price objective on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.